ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1036

Blood Glucose Changes Surrounding Initiation of Tumor-Necrosis Factor Inhibitors and Conventional Disease-Modifying Anti-Rheumatic Drugs in Veterans with Rheumatoid Arthritis

Patrick R. Wood1, Evan Manning2, Joshua Baker3, Grant Cannon4, Lisa Davis5, Bryant R. England6, Ted R. Mikuls7 and Liron Caplan8, 1Rheumatology, University of Colorado School of Medicine, Aurora, CO, 2University of Colorado School of Medicine, Aurora, CO, 3Rheumatology, University of Pennsylvania, Philadelphia, PA, 4Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, 5Div of Rheumatology, Denver Health, Denver, CO, 6Division of Rheumatology & Immunology, Department of Internal Medicine, Nebraska-Western IA VA Health Care System & University of Nebraska Medical Center, Omaha, NE, 7Internal Medicine, Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, 8Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Comorbidity, DMARDs, drug safety, rheumatoid arthritis (RA) and tumor necrosis factor (TNF)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 6, 2017

Title: Health Services Research Poster II: Osteoarthritis and Rheumatoid Arthritis

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: There is evidence linking activation of the innate immune system and insulin resistance.  Perturbations in glucose homeostasis upon initiation of tumor-necrosis factor inhibitors (TNFis) and conventional DMARDs have been described in small studies, perhaps due to suppression of inflammation.  To evaluate this association, we measured glucose before and after initiation of TNFis and DMARDS in a large registry of patients with rheumatoid arthritis (RA).

Methods: Patients enrolled in the Veterans Affairs RA (VARA) registry were retrospectively examined.  Subjects were selected who, during study follow-up, initiated treatment with TNFis, prednisone, or DMARDs, and for whom proximate random blood glucose (RBG) or hemoglobin A1C (A1C) values were available.  Proximate values were the closest RBG within 2 weeks prior to, and 6 months following, medication initiation.  A1C values were the closest A1C within 2 months prior to, and 12 months following, medication initiation.  Measurements were compared before and after medication initiations using paired t-tests and multivariate regression, adjusting for demographics and comorbid conditions.

Results: 2111 patients contributed at least one proximate measurement surrounding initiation of any agent. Significant decreases in RBG were associated with 653 hydroxychloroquine-initiation events (-3.68mg/dL, p =0.04), and increases were noted in RBG surrounding 665 prednisone-initiation events (+5.85mg/dL, p <0.01).  A significant decrease in A1C was noted surrounding 49 sulfasalazine-initiation events (-0.70%, p <0.01).  Multivariate regression analyses suggest sulfasalazine and hydroxychloroquine use as predictors of lower post-medication-initiation blood glucose values; congestive heart failure was also a predictor for higher RBG values after all medication-initiation events. We found no association of TNFi initiation with changes in glucose.

Conclusion: This study quantifies hyperglycemic effects of prednisone initiation. We also observed hypoglycemic effects of sulfasalazine and hydroxychloroquine initiation.   TNFi initiation was not observed to impact measured blood glucose.  Further large-scale and prospective investigation of DMARD and TNFi blood glucose effects in other populations is warranted.

 


Disclosure: P. R. Wood, None; E. Manning, None; J. Baker, None; G. Cannon, Amgen, 2; L. Davis, None; B. R. England, None; T. R. Mikuls, BMS, 2,Ironwood Pharm, 2,Pfizer Inc, 5,NIH, VA, 2; L. Caplan, None.

To cite this abstract in AMA style:

Wood PR, Manning E, Baker J, Cannon G, Davis L, England BR, Mikuls TR, Caplan L. Blood Glucose Changes Surrounding Initiation of Tumor-Necrosis Factor Inhibitors and Conventional Disease-Modifying Anti-Rheumatic Drugs in Veterans with Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/blood-glucose-changes-surrounding-initiation-of-tumor-necrosis-factor-inhibitors-and-conventional-disease-modifying-anti-rheumatic-drugs-in-veterans-with-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/blood-glucose-changes-surrounding-initiation-of-tumor-necrosis-factor-inhibitors-and-conventional-disease-modifying-anti-rheumatic-drugs-in-veterans-with-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology